Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | BHMT | Q93088 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 2/20 | 0.32 |
| ▸ | GABRD | O14764 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3955384 | 1.00 | METAP1 (0.38) | METAP1MAPTMETAP2ANPEPSLC1A3 | |
| SCHEMBL3962889 | 1.00 | METAP1 (0.38) | METAP1MAPTMETAP2ANPEPSLC1A3 | |
| SCHEMBL3967280 | 0.97 | METAP1 (0.41) | METAP1MAPTMETAP2SLC1A3SLC1A2 | |
| SCHEMBL3958014 | 0.97 | METAP1 (0.41) | METAP1MAPTMETAP2SLC1A3SLC1A2 | |
| SCHEMBL3958292 | 0.97 | METAP1 (0.41) | METAP1MAPTMETAP2SLC1A3SLC1A2 | |
| SCHEMBL3961044 | 0.95 | METAP1 (0.44) | METAP1MAPTMETAP2SLC1A3SLC1A2 | |
| SCHEMBL3958667 | 0.95 | METAP1 (0.44) | METAP1MAPTMETAP2SLC1A3SLC1A2 | |
| SCHEMBL3966987 | 0.95 | METAP1 (0.44) | METAP1MAPTMETAP2SLC1A3SLC1A2 | |
| SCHEMBL3958285 | 0.95 | METAP1 (0.44) | METAP1MAPTMETAP2SLC1A3SLC1A2 | |
| SCHEMBL3958289 | 0.95 | METAP1 (0.44) | METAP1MAPTMETAP2SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE | 2006-11-02 | — | — | US | claimed |
| US-7112610-B2 | Methods for using amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2006-09-26 | — | — | US | claimed |
| EP-1492761-B1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WARNER LAMBERT CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7517909-B2 | Amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-04-14 | — | — | US | disclosed |
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE | 2006-11-02 | — | — | US | disclosed |
| US-7112610-B2 | Methods for using amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY S | 2006-07-13 | — | — | US | disclosed |
| EP-1670452-A2 | METHOD OF USE OF AMINOACIDS HAVING AFFINITY FOR THE A2D PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7064147-B2 | Amino acids with affinity for the α-2-delta-protein | WARNER-LAMBERT COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1614675-A2 | Amino acids with affinity for the alpha-2-delta protein | Warner-Lambert Company LLC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | BARTA NANCY SUE | 2005-12-08 | — | — | US | disclosed |
| US-20050124669-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2005030184-A2 | THERAPEUTIC BETA AMINOACIDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| EP-1492761-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY SUE (US) | 2003-10-16 | — | — | US | disclosed |
| WO-2003082807-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124669-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | METAP1 1286/4885MAPT 1415/4885METAP2 651/4885 |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, CAMK2A | METAP1 809/4885MAPT 1240/4885METAP2 371/4885 |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | METAP1 1550/4885MAPT 878/4885METAP2 859/4885 |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, SCN1A | METAP1 1539/4885MAPT 646/4885METAP2 957/4885 |
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | METAP1 1286/4885MAPT 1415/4885METAP2 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.